Deep Track Capital LP Has $5.71 Million Stock Position in Inovio Pharmaceuticals, Inc. (NASDAQ:INO)

Deep Track Capital LP increased its stake in shares of Inovio Pharmaceuticals, Inc. (NASDAQ:INO - Free Report) by 72.9% during the fourth quarter, according to the company in its most recent filing with the SEC. The fund owned 3,119,162 shares of the biopharmaceutical company's stock after acquiring an additional 1,314,796 shares during the period. Deep Track Capital LP owned 11.95% of Inovio Pharmaceuticals worth $5,708,000 as of its most recent filing with the SEC.

A number of other institutional investors have also made changes to their positions in the stock. Alpine Global Management LLC bought a new stake in Inovio Pharmaceuticals during the fourth quarter valued at about $31,000. Bank of Montreal Can acquired a new stake in Inovio Pharmaceuticals in the 4th quarter valued at approximately $43,000. Boothbay Fund Management LLC bought a new position in Inovio Pharmaceuticals in the 4th quarter worth approximately $44,000. Barclays PLC lifted its holdings in shares of Inovio Pharmaceuticals by 282.6% during the third quarter. Barclays PLC now owns 34,003 shares of the biopharmaceutical company's stock worth $197,000 after buying an additional 25,116 shares during the last quarter. Finally, Jane Street Group LLC lifted its holdings in shares of Inovio Pharmaceuticals by 118.2% during the fourth quarter. Jane Street Group LLC now owns 39,704 shares of the biopharmaceutical company's stock worth $73,000 after buying an additional 21,512 shares during the last quarter. 26.79% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

A number of equities analysts recently issued reports on INO shares. Royal Bank of Canada dropped their target price on shares of Inovio Pharmaceuticals from $6.00 to $5.00 and set a "sector perform" rating on the stock in a research report on Wednesday, March 19th. StockNews.com downgraded shares of Inovio Pharmaceuticals from a "hold" rating to a "sell" rating in a report on Friday, May 2nd. HC Wainwright reiterated a "neutral" rating and issued a $3.00 target price on shares of Inovio Pharmaceuticals in a research note on Wednesday, March 19th. Finally, JMP Securities reissued a "market outperform" rating and set a $18.00 target price on shares of Inovio Pharmaceuticals in a research report on Friday, January 10th. One research analyst has rated the stock with a sell rating, two have given a hold rating and three have issued a buy rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of "Hold" and an average price target of $12.20.

Inovio Pharmaceuticals Trading Down 0.3 %

NASDAQ INO traded down $0.01 during trading hours on Friday, reaching $1.82. 427,875 shares of the company's stock were exchanged, compared to its average volume of 587,877. The firm has a fifty day moving average of $1.80 and a 200-day moving average of $2.63. Inovio Pharmaceuticals, Inc. has a one year low of $1.42 and a one year high of $13.44. The stock has a market cap of $66.56 million, a PE ratio of -0.45 and a beta of 1.40.

Inovio Pharmaceuticals (NASDAQ:INO - Get Free Report) last announced its earnings results on Tuesday, March 18th. The biopharmaceutical company reported ($0.69) earnings per share for the quarter, beating analysts' consensus estimates of ($0.87) by $0.18. The business had revenue of $0.12 million during the quarter, compared to analyst estimates of $0.03 million. As a group, research analysts forecast that Inovio Pharmaceuticals, Inc. will post -4.23 EPS for the current year.

About Inovio Pharmaceuticals

Inovio Pharmaceuticals, Inc, a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids.